Scholar Rock Holding Corporation research snapshot
SRRK AI stock analysis currently sees Scholar Rock as a clinical-stage biopharmaceutical company whose lead candidate, apitegromab, targets the activation of myostatin for the treatment of spinal muscular atrophy. SRRK closed at $56.71 on July 10, 2026, giving it an estimated market capitalization of about $4.99 billion. The stock has more than doubled from its 52-week low of $27.07, driven by positive SAPPHIRE Phase 3 data and the ongoing regulatory preparation for apitegromab. Scholar Rock has no approved products or recurring revenue, so the investment case depends entirely on clinical success, regulatory outcomes, commercial execution, and the terms of future financing. This page is an informational research tool, not investment advice.
Current price
$56.71 close on July 10, 2026
Market cap
$4.99 billion calculated from $56.71 x an estimated 88 million shares; exact share count depends on the latest SEC filing
AI score
54 / 100
Rating
Lead SMA asset apitegromab with strong momentum and a wide pipeline beyond, but pre-revenue cash burn and binary regulatory milestones define the risk
Trend status
Strong uptrend above the 50-day and 200-day moving averages, near the 52-week high with elevated momentum and event-driven gap risk
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Scholar Rock is developing a potentially disease-modifying therapy for SMA based on myostatin inhibition. The science is differentiated but the business has no revenue and no approved products, so quality is an unproven thesis, not a track record. | High |
| Moat | Scholar Rock has a potential moat based on its proprietary platform for activating growth factors, clinical data for apitegromab, IP protection, and SMA regulatory exclusivity. The moat is narrow because the SMA treatment market already includes Spinraza, Zolgensma, and Evrysdi. | Medium |
| Management | CEO Jay Backstrom and the team have advanced apitegromab through Phase 3 with positive data and are preparing for regulatory filings. The capital allocation test is whether the company can convert clinical success into a commercially viable product before needing additional financing. | Medium |
| Financial trend | Scholar Rock is pre-revenue and unprofitable. The company funds operations through equity offerings and partnership payments. Cash and investments provide the runway to key catalysts but will eventually require additional capital to fund commercialization. | High |
| Valuation | At $56.71, Scholar Rock has no positive P/E, no revenue multiple, and negative free cash flow. The valuation is a market bet on the probability and commercial scale of apitegromab approval and adoption, not a reflection of current earnings. | Medium-high |
| Technical trend | The stock has rallied sharply from the 52-week low of $27.07 and sits near its high of $58.49. The uptrend is intact but momentum is extended, and event-driven gaps can trigger large moves in either direction regardless of the chart pattern. | Medium |
| Risk level | Very high. Clinical-stage biotech risk includes regulatory denial, commercial adoption failure, safety signals, pipeline setbacks, cash burn, dilution, competition from approved SMA therapies, and binary event risk around FDA decisions. | High |
| AI confidence | Historical facts and reported data have high AI confidence. Forward scenarios, regulatory probabilities, market adoption rates, and price outcomes have low-to-medium AI confidence because they depend on events that have not happened yet. | Medium |
| Investment certainty | Investment certainty is low for a pre-revenue biotech. Even successful FDA approval does not guarantee commercial success, and the path to self-sustaining profitability is several years and multiple financing rounds away. | Low |
SRRK AI stock forecast
The SRRK AI stock forecast uses scenario ranges rather than a single target because the stock is driven by binary regulatory events. The required three-scenario calculation produced negative reference values because TTM EPS is negative, so the practical ranges below focus on regulatory timing, commercial probability, and financing risk.
$80 to $120 scenario range
More likely if apitegromab receives FDA approval with a broad label covering both non-ambulant and ambulant SMA patients, the launch shows strong patient and physician adoption, European and ex-US regulatory approvals follow, and pipeline assets like SRK-439 or SRK-181 show clinical progress without excessive cash burn.
$45 to $80 scenario range
More likely if apitegromab is approved with a narrower label, launch uptake is gradual due to competition and payer constraints, cash burn continues through the commercial launch phase, and the company raises additional equity capital to fund operations.
$15 to $45 scenario range
More likely if the FDA requires additional data or issues a complete response letter, the safety profile shows unexpected signals, commercial uptake disappoints against existing SMA therapies, a pipeline trial fails, or the company needs to raise capital at a deeply discounted price.
SRRK AI technical analysis
SRRK AI technical analysis uses the July 10, 2026 close and StockAnalysis indicators available at the cutoff. This static page does not fetch live chart data. Confirm support, resistance, moving averages, momentum, volume, and invalidation levels in a live chart before acting. Event-driven biotech news can overwhelm any technical pattern.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $56.71 | July 10, 2026 close on Nasdaq. The session high of $58.49 matched the stock's 52-week high. |
| Near support | $52 to $55 | A planning zone below the recent close. It is not a guaranteed floor and should be checked against live price action. |
| Trend support | $44 to $46 | The November 2025 breakout level near $44.06 and the April 2026 close near $46.61 define a longer-term support zone. |
| Near resistance | $58.49 (52-week high) | A clean breakout above this level with volume would open a new price range. Without a fundamental catalyst, it is a reference, not a target. |
| Moving averages | 50-day and 200-day averages below current price | The stock trades above both moving averages, which supports the uptrend. The exact values require a real-time quote refresh. |
| Momentum | Strong but extended | The stock has rallied more than 100% from the 52-week low. Momentum indicators near overbought territory increase pullback risk. |
| Volume | 818,735 shares on July 10 | Check whether breakouts or breakdowns are confirmed by volume significantly above the recent average daily volume. |
| Volatility | High, typical for clinical-stage biotech | SRRK can gap 10-30% on regulatory news, clinical data, or financing announcements. Ordinary volatility measures understate tail risk. |
| Invalidation | Close below $44 | A decisive break below the November 2025 breakout zone would weaken the longer-term chart structure. A regulatory event can override all technical levels. |
SRRK AI trading strategy
The SRRK AI trading strategy is a rules-based research framework, not personalized advice. Use a live chart, an FDA clinical calendar, current filings, position sizing, and a plan for overnight gaps because biotech catalysts can overwhelm ordinary stops.
Wait for SRRK to hold above the $52 to $55 planning zone and clear the $58.49 52-week high with volume that exceeds the recent average, while a fundamental catalyst such as a regulatory filing, advisory committee date, or approval announcement supports the move.
A failed breakout or a decisive close below $52 should invalidate the trend setup. Biotech gaps can overrun ordinary stops, so adjust position size accordingly.
If SRRK pulls back without a business-thesis break, compare the price with the cash runway, regulatory timeline, clinical data quality, and competitive positioning. A pullback to the $44 to $46 trend support may offer a reference entry for investors who assign high probability to approval.
Do not average down unless maximum loss, position size, and a fundamental invalidation condition are set in advance. A failed trial or regulatory setback can cut the stock by 50-70% in a single session.
Track the apitegromab FDA BLA submission and review timeline, any advisory committee meeting, trial data updates for SRK-439 and SRK-181, cash and investments, operating burn, share count, and any partnership or financing announcements.
Reduce confidence if the regulatory timeline slips, safety signals emerge, cash burn accelerates without matching clinical progress, or the company issues equity at a price that dilutes existing holders significantly.
Investment research summary
Scholar Rock is developing apitegromab, a monoclonal antibody that selectively inhibits the activation of myostatin, for the treatment of spinal muscular atrophy. Patients and physicians pay for a novel mechanism that could complement or compete with existing SMN-enhancing therapies. The company has no approved products, so the business case is entirely a bet on clinical and regulatory outcomes. Buffett-style question: would this still be a good business if the pipeline beyond apitegromab disappeared?
Scholar Rock has a developing moat from its proprietary platform for activating growth factors, the clinical evidence for apitegromab, IP protection, and potential FDA orphan-drug and pediatric exclusivity. The SMA treatment market is competitive and includes Spinraza (Biogen), Zolgensma (Novartis), and Evrysdi (Roche). Switching costs to apitegromab would depend on physician education, patient experience, and long-term data. Buffett-style question: ten years after a well-funded competitor enters with a better or safer myostatin inhibitor, how much of Scholar Rock value would remain?
The thesis can fail in several ways. The FDA may require additional trials or issue a complete response letter. Even if approved, apitegromab may not achieve commercial expectations against established SMA therapies with strong safety and efficacy profiles. Pipeline candidates SRK-439 and SRK-181 may fail in earlier-stage trials. Cash burn may force equity financing that dilutes existing holders. Munger-style question: what single fact would make the current valuation look obviously too optimistic?
CEO Jay Backstrom and the board have guided apitegromab through Phase 3 success and are preparing regulatory filings. Capital allocation has focused on pipeline advancement, with the SAPPHIRE trial and supporting studies consuming the operating budget. The company had cash and investments to fund operations through key milestones, but commercial launch preparation and pipeline expansion will require additional capital. Management question: if the CEO left, would the clinical and regulatory engine still function?
SMA treatment is shifting from SMN-enhancing therapies alone toward combination approaches that address muscle function and survival. Apitegromab, as a myostatin inhibitor, targets the muscle weakness component that existing SMN therapies do not fully address. The rare-disease neuromuscular market has clear regulatory pathways, strong pricing precedent, and motivated patient communities. Li Lu-style question: in twenty years, will myostatin inhibition be a standard component of SMA care or an abandoned hypothesis?
At $56.71, the estimated market value is about $4.99 billion against zero revenue, negative earnings, and negative free cash flow. The price reflects the market assessment of apitegromab approval probability, commercial scale, and pipeline optionality. The margin of safety is minimal unless the reader is willing to assign a high probability to successful FDA approval and significant commercial adoption. Buffett-style question: if the stock market closed for five years, would this price be justified by the cash flows the business could produce in that time?
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SRRK closing price and range | $56.71 close on July 10, 2026; high $58.49; low $55.14; volume 818,735 shares | Yahoo Finance chart data via NASDAQ | July 12, 2026 |
| Market capitalization estimate | $4.99B calculated from $56.71 x an estimated 88 million shares; share count needs SEC filing confirmation | Yahoo Finance price data; share count estimated from public filings | July 12, 2026 |
| 52-week price range | Low $27.07; high $58.49 | Yahoo Finance chart data | July 12, 2026 |
| Recent clinical catalyst | Positive topline SAPPHIRE Phase 3 results for apitegromab in non-ambulant SMA patients; BLA preparation underway | Scholar Rock press release and SEC filings | July 12, 2026 |
| Cash and investments | Cash and investments sufficient to fund operations through key regulatory and clinical milestones | Scholar Rock SEC filings and investor presentations | July 12, 2026 |
| Pipeline overview | Apitegromab (Phase 3 SMA); SRK-439 (preclinical SMA); SRK-181 (Phase 1 cancer); research-stage programs in cardiac and metabolic disease | Scholar Rock pipeline page and investor materials | July 12, 2026 |
| Competitive context | Existing SMA therapies: Spinraza (Biogen), Zolgensma (Novartis), Evrysdi (Roche). Apitegromab is a myostatin inhibitor with a potentially complementary mechanism. | Published SMA treatment reviews and company materials | July 12, 2026 |
| Technical snapshot | Stock above 50-day and 200-day moving averages; near 52-week high of $58.49; RSI extended after the recent rally | StockAnalysis and Yahoo Finance technical indicators | July 12, 2026 |
| Valuation notes | Pre-revenue biotech with no positive P/E, no revenue multiple, negative free cash flow. Valuation is a function of clinical probability. | Financial analysis based on SEC filings | July 12, 2026 |
This SRRK AI stock analysis page is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, SEC filings, clinical and regulatory updates, competitive dynamics, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
